Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases

BACKGROUND: Six radium-223 injections at 4-week intervals is indicated for patients with castration-resistant prostate cancer and symptomatic bone metastases. However, patients usually develop disease progression after initial treatment. This prospective phase I/II study assessed re-treatment safety...

Descripción completa

Detalles Bibliográficos
Autores principales: Sartor, O., Heinrich, D., Mariados, N., Méndez Vidal, M. J., Keizman, D., Thellenberg Karlsson, C., Peer, A., Procopio, G., Frank, S. J., Pulkkanen, K., Rosenbaum, E., Severi, S., Trigo Perez, J. M., Wagner, V., Li, R., Nordquist, L. T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834059/
https://www.ncbi.nlm.nih.gov/pubmed/28961839
http://dx.doi.org/10.1093/annonc/mdx331

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834059/
https://www.ncbi.nlm.nih.gov/pubmed/28961839
http://dx.doi.org/10.1093/annonc/mdx331

Ejemplares similares